HLA antigens in patients with variant angina in Japan

There have been few reports on examining the susceptibility of variant angina. Accordingly, the major histocompatibility complexes (HLA-A, -B, -C, -DR) of unrelated Japanese patients with variant angina were examined. There were no significant differences in the frequency of HLA-A,-B, -C, and -DR antigens between patients and controls (n = 100). Although endothelial dysfunction with pathological abnormalities is suggested to be one of the etiological factors in vasospasm, immunogenetic abnormalities linked to HLA system might not play a role in the pathogenesis of variant angina.     

放射事故受照者血型糖蛋白A突变分析

目的研究血型糖蛋白Ａ（ＧＰＡ,ｇｌｙｃｏｐｈｏｒｉｎＡｌｏｃｕｓ）突变分析用作新的辐射生物剂量计。方法结合流式细胞分析和单克隆抗体标记技术,检测红细胞糖蛋白的变异。结果随访全国１０例放射源事故受照者,４人为ＭＮ杂合体,生物剂量在１４６～２９Ｇｙ,１人ＭＮ弱阳性。ＧＰＡＮＯ变异率与剂量线性回归曲线有显著意义,曲线斜率４１５３×１０－６／Ｇｙ,而ＮＮ没有显著意义。结论ＧＰＡ变异率剂量效应曲线二次线性拟合比一次线性好。二次线性重建远期辐射剂量高于一次模型,用原爆、切尔诺贝利、戈亚尼亚事故参数回顾剂量多偏高。     

Coronary spasm: It’s common,but it’s still unsolved

Coronary spasm is caused by a transient coronary narrowing due to the constriction of epicardial coronary artery, which leads to myocardial ischemia. More than 50 years have passed since the first recognition of coronary spasm, and many findings on coronary spasm have been reported. Coronary spasm has been considered as having pivotal roles in the cause of not only rest angina but also exertional angina, acute coronary syndrome, and heart failure. In addition, several new findings of the mechanism of coronary spasm have emerged recently. The diagnosis based mainly on coronary angiography and spasm provocation test and the mainstream treatment with a focus on a calcium-channel blocker have been established. At a glance, coronary spasm or vasospastic angina (VSA) has become a common disease. On the contrary, there are several uncertain or unsolved problems regarding coronary spasm, including the presence of medically refractory coronary spasm (intractable VSA), or an appropriate use of implantable cardioverter defibrillator in patients with cardiac arrest who have been confirmed as having coronary spasm. This editorial focused on coronary spasm, including recent topics and unsolved problems.     

Variant angina pectoris associated with FOLFOX4 therapy

The patient was a 71-year-old man who underwent a right hemicolectomy for ascending colon cancer(pT3,pN1,pM0) and who opted not to receive adjuvant chemotherapy.Eight months later,multiple liver metastases occurred.He therefore received FOLFOX4(5-fluorouracil/leucovorin and 85 mg/m 2 oxaliplatin) therapy,up to a total of 5 courses,and showed a partial response.While receiving the sixth course of FOLFOX4,he complained of chest pain and systemic itching approximately 15 min after the start of chemo-therapy.An electrocardiogram revealed typical signs of ischemia.Coronary arteriography showed that the coronary arteries were intact.Believing the chest pain to be merely coincidental,we continued with the same therapy.However,he again developed the same chest pain during the seventh cycle of FOLFOX4 and treatment was stopped.We concluded that the patient’s symptoms were due to acute coronary syndrome(ACS) associated with the FOLFOX4 regimen.Variant angina as a type of ACS is a rare adverse effect of FOLFOX4. Clinicians should be aware of this potential adverse effect when monitoring patients receiving FOLFOX4.     

咳嗽变异性哮喘的临床分析

目的观察临床治疗咳嗽变异性哮喘（cough variant asthma,CAV）的疗效,减少误诊误治。方法选取2001年2月至2003年6月门诊及住院共78例病人,分析78例确诊为咳嗽变异性哮喘患者的临床特点及治疗方法。结果 78例中治愈56例,显效14例,8例发展成慢性支气管哮喘。结论咳嗽变异性哮喘又名过敏性咳嗽,是哮喘的一种变异形式,被确诊为咳嗽变异性哮喘的患者不用过分担心,只要在医生的指导下进行适当的抗炎解痉治疗,一般都能有效地缓解咳嗽症状,避免发展为典型哮喘。     

伴有t(8;21)变异易位的急性髓系白血病患儿二例遗传学研究

 【摘要】　目的　报道2例分别伴有t(8;20)(q22;q13)和t(1;8;21) (q32;q22;q22)的t(8;21)变异易位的M2型急性髓系白血病（AML-M2）。方法　骨髓细胞短期培养法制备染色体标本,应用反带和吉姆萨显带技术进行核型分析;双色双融合AML1-ETO探针进行间期及中期双色荧光原位杂交（D-FISH）检测AML1-ETO融合信号;多重巢式反转录-聚合酶链反应（ RT-PCR）技术检测AML1-ETO融合基因转录本。结果　例1 核型为45,X,-Y, t (8;20)(q22;q13) [12]／46,XY[3],例2 核型为46,XX,t(1;8;21)(q32;q22;q22)[18]／46,XX[2];间期和中期FISH证实了AML1-ETO融合基因和变异易位的存在;多重巢式RT-PCR检测到AML1-ETO融合基因转录本。结论　t(8;20)(q22;q13)和t(1;8;21)(q32;q22;q22)实质上都是t(8;21)的变异型易位;核型分析联合D-FISH、多重巢式RT-PCR对确定伴有变异型t(8;21)易位的AML患者的性质和预后是重要的。     

Glutathione S-transferase A1 polymorphism and the risk of recurrent spontaneous abortion in Chinese Han population

Objective

Recurrent spontaneous abortion (RSA) is a multifactor and distressing disease. There are still approximately half of the RSA patients with cause not being identified to date. Accumulating studies have confirmed that genetic polymorphisms in glutathione S-transferases (GSTs) were associated with the risk of recurrent spontaneous abortion. In this study, we aimed to investigate the relationship between the polymorphism of GSTA1, which is GSTA1 -69C/T (rs3957357), and the development of recurrent spontaneous abortion.

Methods

A case–control study of 127 cases with RSA and 112 ethnic and age matched women as controls was conducted. And measurement of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was performed to genotype all of samples in order to analyze the association between GSTA1 -69C/T (rs3957357) and the risk of RSA.

Results

We found that the frequencies of genotypes between cases and controls have no significant difference (P = 0.908) and GSTA1 mutant allele GSTA1 −69 T was present at a frequency of 0.122 in case group, while in controls the frequency was 0.125 (P = 0.922).

Conclusion

The polymorphism of GSTA1 (rs3957357) may not be associated with the risk of recurrent spontaneous abortion in Chinese Han population.     

Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice

Factor H-binding protein (fHbp) is a component of a meningococcal vaccine recently licensed in Europe for prevention of serogroup B disease, and a second vaccine in clinical development. The protein specifically binds human factor H (fH), which down-regulates complement activation and enhances resistance to bactericidal activity. There are conflicting data from studies in human fH transgenic mice on whether binding of human fH to fHbp vaccines decreases immunogenicity, and whether mutant fHbp vaccines with decreased fH binding have enhanced immunogenicity. fHbp can be classified into two sub-families based on sequence divergence and immunologic cross-reactivity. Previous studies of mutant fHbp vaccines with low fH binding were from sub-family B, which account for approximately 60% of serogroup B case isolates. In the present study, we evaluated the immunogenicity of two mutant sub-family A fHbp vaccines containing single substitutions, T221A or D211A, which resulted in 15- or 30-fold lower affinity for human fH, respectively, than the corresponding control wild-type fHbp vaccine. In transgenic mice with high serum concentrations of human fH, both mutant vaccines elicited significantly higher IgG titers and higher serum bactericidal antibody responses than the control fHbp vaccine that bound human fH. Thus, mutations introduced into a sub-family A fHbp antigen to decrease fH binding can increase protective antibody responses in human fH transgenic mice. Collectively the data suggest that mutant fHbp antigens with decreased fH binding will result in superior vaccines in humans.